Ad5 vectored COVID-19 vaccine shows potential in first human trial
The novel Ad5 vectored COVID-19 (Ad5-nCoV) vaccine is safe, well-tolerated, and induces rapid immune response against SARS-CoV-2 in healthy adults, reveal data from the first-in-human trial for a COVID-19 vaccine.